

1. A method for identifying tumor characteristics comprising:

2. The method of claim 1, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, Edg 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

3. The method of claim 1, wherein at least one of the genes associated with lipid metabolism, synthesis, or action is selected from the group consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
4. The method of claim 1, wherein the determination of the copy number of the genes associated with lipid metabolism, synthesis, or action is made by:

isolating sample nucleic acid polymers from cells of the patient tissue sample;

hybridizing the sample nucleic acid polymers with nucleic acid polymers specific for the selected genes to quantify the extent of hybridization; and

comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as the patient tissue sample.

5. The method of claim 4, wherein the sample nucleic acid polymer in the isolating step is amplified by a polymerase chain reaction (PCR).
6. The method of claim 4, wherein the step of hybridizing the sample nucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a coding region of one of the selected genes.

- [illegible]

Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1
glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase,
Phosphatidic Acid Phosphate type 2b, Edg 1, Glycerol-3-phosphate dehydrogenase,
Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN),
Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-
acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma,
Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3,
EDG 4, EDG 5, EDG 6, and EDG 7.

11. The method of claim 9, wherein at least one of the genes associated with lipid metabolism, synthesis, or action is selected from the group consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
12. The method of claim 9, wherein the determination of the expression level of the genes associated with lipid metabolism, synthesis, or action is made by:

isolating sample ribonucleic acid polymers from the cells of the patient tissue sample;

hybridizing the sample ribonucleic acid polymers with nucleic acid polymers specific for the selected genes to quantify the extent of hybridization; and

comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as the patient tissue sample.

13. The method of claim 12, wherein the sample ribonucleic acid polymer in the isolating step is amplified by a polymerase chain reaction (PCR) technique.

14. The method of claim 12, wherein the step of hybridizing the sample ribonucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a coding region of one of the selected genes.

15. The method of claim 12, wherein the step of hybridizing the sample ribonucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a non-coding sequence functionally linked to the coding region of one of the selected genes, wherein the functionally linked non-coding sequence is unique to that gene.

16. The method of claim 12, wherein the hybridizing step uses nucleic acid polymers specific for the selected genes that are immobilized on a solid support wherein a nucleic acid polymer specific for each selected gene is located at a predetermined position on the solid support.

17. An array of nucleic acid polymers immobilized on a solid support, comprising:
a solid support;

Sub
a7

at least two different nucleic acid polymers which are each specific for a different gene associated with lipid metabolism, synthesis, or action;

wherein each nucleic acid polymer is located at a predetermined position on the solid support, and wherein the array comprises nucleic acid polymers which are specific for less than 100 genes other than the selected genes.

18. The array of claim 17, wherein at least two of the nucleic acid polymers are specific for genes selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Phosphatidic Acid Phosphatase type 2c, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, Edg 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Acyl-dihydroxyacetone phosphate reductase, Triacylglycerol lipase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

- OC-48964.1